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the group of 416 allografted patients, the cumulative prob-
ability of SMN being 6.8 at 10 years. Since the number of
expected cases in the general population is 0.62, the ratio of
observed to expected cases is 3.2 (p < 0.001). This ﬁgure
means that the risk of developing a malignant neoplasm in
allografted individuals using our method is 3.2 times higher
than that in the general population. There were three non-
Hodgkin’s lymphomas (NHL), two M2 acute myelogenous
leukemias (AML), one hairy cell leukemia, one tongue
epidermoid carcinoma and one breast carcinoma. In
conclusion, we have found a low incidence of SMN in this
group of Mexican patients allografted with the Mexican
reduced-intensity conditioning method. Possible explana-
tions for this difference are discussed, focusing on the RIC
preparative regimen.387
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Objective: To demonstrate the efﬁcacy and safety of a
reduced intensity conditioning (RIC) regimen comprising
Fludarabine and intravenous Busulfan (FB2) in patients un-
dergoing allogeneic peripheral blood stem cell trans-
plantation (PBSCT) for hematological disorders.
Patients and Methods: We conducted a retrospective anal-
ysis of 42 patients who underwent RIC prior to PBSCT at our
institution between the years 2009 and 2012 inclusive. FB2
consisted of Fludarabine 30 mg/m2/day infused over 30 mi-
nutes for 5 days on days -6 through -2 and Busulfan 3.2 mg/
kg/day on days -3 and -2 (infusion rate 80 mg/kg/hour). All
patients received Thymoglobulin at a total dose of 4.5 mg/kg
or 6 mg/kg administered in divided doses on days -2, -1 and
0. Post-transplantation graft versus host disease (GVHD)
prophylaxis consisted of tacrolimus and mycophenolate
mofetil. Diagnoses included Acute Myeloid Leukemia (n¼3),
Acute Lymphoblastic Leukemia (n¼2), Myelodysplastic Syn-
drome (n¼10), Severe Aplastic Anemia (n¼5), Chronic Lym-
phocytic Lymphoma (n¼8), Non-Hodgkin’s Lymphoma
(n¼8), Hodgkin Lymphoma (n¼4) and Myeloproliferative
Disorder (n¼2). The median age of the recipients was 56
years with 18 patients (44%) aged> 60 years. Only 9 patients
(21%) were in complete remission (CR) at the time of HSCT
and 19 (45%) were considered to have high-risk disease by
CIBMTR criteria. The co-morbidity index was 3 or more in 19
recipients (45%).
Results: At a median follow up of 15 months, overall survival
(OS) for the entire cohort was 62%. OS for patients under-
going PBSCT in CR versus not in CR was 89% and 55%
respectively. OS was similar in recipients undergoing PBSCT
from matched unrelated (n¼29) or matched related (n¼13)
donors. Median engraftment time for neutrophils (ANC>500) and platelets (>20K) was 18 and 17 days, respectively.
Acute GVHD grade 2 developed in 15 (36%) of recipients,
grade 3 in 2 (5%) and grade 4 in 2 (5%). The cumulative
incidence of relapse was 37% (n¼13). There were no graft
failures and treatment relatedmortality (TRM)was 2% (n¼1).
At one year following PBSCT, 10 patients (24%) had extensive
chronic GVHD and 19 patients (45%) required continuation of
immunosuppressants. All patients with SAA (n¼5) are alive,
engrafted and did not develop grade 3 or 4 acute GVHD.
Conclusion: Our preliminary data demonstrates low toxicity
and favorable outcome in older patients with elevated co-
morbidity score and high-risk disease using the FB2 regimen.
The efﬁcacy, tolerability and excellent outcome of FB2 war-
rants further study in recipients with SAA.388
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Introduction: Graft Versus Host Disease (GVHD) and
immunosuppression in allogeneic hematopoietic stem cell
transplant (alloHSCT) patients can contribute to cytomega-
lovirus (CMV) disease. CMV disease of the gut is associated
with intestinal necrosis and ulceration and can lead to
debilitating diarrhea. Diagnostic evaluation includes assess-
ment for CMV viremia and intestinal biopsy to conﬁrm
diagnosis. Adequate research supporting intestinal biopsy in
serum negative patients does not exist. In an effort to
potentially minimize use of invasive endoscopic procedures
to rule out CMV as a cause for diarrhea, we evaluated the
diagnostic yield of intestinal biopsies in the work-up of
allograft recipients presenting with diarrhea.
Methods: This retrospective study evaluated a total of 485
patients that underwent alloHSCT after 2006 and were
admitted to the inpatient BMT service between January 1st,
2008 and April 30th, 2013. A subset of patients was identiﬁed
that completed esophagogastroduodenoscopy (EGD) or co-
lonoscopy for work-up of diarrhea. Comparisons were made
between serum CMV PCR (108 bp primer directed at CMV
Immediate Early antigen product) and gastrointestinal bi-
opsy (with morphologic evaluation for cytopathic effect and
immunohistochemistry for immediate early non-structural
antigen). Pathologic evaluation conﬁrmed gut-associated
CMV disease.
Results: CMV viremia was evident the day of intestinal bi-
opsy 25% (99 total biopsies) of the time. Nine biopsies (9%) in
7 different patients were positive for CMV and conﬁrmed
CMV gut disease. Of these, 6 patients had corresponding
CMV viremia. One patient (cord blood recipient) was diag-
nosed with CMV gut disease by biopsy alone. Signiﬁcant
association (p¼0.003) and agreement (p¼0.006) between
CMV viremia and CMV gut disease were observed in this
cohort, although we do note discordances of interest. No
apparent association between lymphocyte count and the
presence of CMV intestinal diseasewas observed (p¼0.23). In
